Screening Kit for Cancer Research
LISTED UNDER:
AMSBIO has announced a new PD-1 (Programmed Death) inhibitor screening assay kit for cancer research studies.
Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. The net result of this targeted approach is decreased toxicity and increased efficacy of immunotherapy. The understanding of the checkpoint signalling pathway involving the programmed death 1 (PD-1) receptor and its ligands (PD-L1/2) in tumor-induced immune suppression has been a critical advancement in immunotherapeutic drug development.
Cell signaling through the PD-1 receptor upon binding the PD-L1 ligand attenuates immune responses and is exploited by both tumors and viruses. The PD-L1 Inhibitor Screening Assay Kit from AMSBIO is designed for screening and profiling inhibitors of this signaling. This kit comes in a convenient 96-well format, with biotin-labeled PD-1, purified PD-L1 or PD-L2, streptavidin labeled HRP, and assay buffer for 100 binding reactions. The key to this kit is the high sensitivity of detection of biotin-labeled PD-1 by streptavidin-HRP. Only a few simple steps on a microplate are required for the assay.
AMSBIO LLC, 1.800.987.0985, www.amsbio.com
